Search

Arvinas Inc

Chiusa

SettoreSettore sanitario

8.27 -0.36

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.18

Massimo

8.28

Metriche Chiave

By Trading Economics

Entrata

227M

169M

Vendite

234M

250M

P/E

Media del settore

32.308

56.432

EPS

2.58

Margine di Profitto

67.841

Dipendenti

246

EBITDA

216M

159M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+80.51% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

29M

549M

Apertura precedente

8.63

Chiusura precedente

8.27

Notizie sul Sentiment di mercato

By Acuity

50%

50%

115 / 339 Classifica in Healthcare

Arvinas Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2026, 19:36 UTC

Arvinas Inc is higher today, advancing since Wednesday's close, despite earlier pulling back from a session high but remaining above its opening level.

16 set 2026, 19:03 UTC

Arvinas Inc shares fell sharply, continuing a downward trend and remaining below the 20-day moving average, with no recovery from an early dip.

15 set 2026, 20:02 UTC

Arvinas Inc shares are trading lower, marking six consecutive daily declines. The stock remains below its 20-day moving average amid negative market sentiment.

11 set 2026, 20:08 UTC

Arvinas Inc. shares are lower today, remaining below their 20-day moving average amid broader market inflation concerns following recent Consumer Price Index data.

10 set 2026, 20:07 UTC

Arvinas Inc shares are lower today, marking four consecutive sessions of declines amid broader market trends and rising Treasury yields.

2 set 2026, 19:46 UTC

Arvinas Inc shares are higher during Wednesday's session, showing unusual strength despite a slight pullback from earlier highs. No specific news was identified.

28 ago 2026, 20:08 UTC

Arvinas Inc. shares are lower as U.S. Treasury yields rise amid inflation concerns. Trading remains routine, with shares finishing below earlier highs.

27 ago 2026, 19:36 UTC

Arvinas Inc. shares are higher during Thursday's session, trading within a narrow range and above the 20-day moving average.

26 ago 2026, 20:08 UTC

Arvinas Inc shares are lower today as the pharmaceuticals sub-sector declines amid broader market weakness since Tuesday's close. No specific news was identified.

25 ago 2026, 23:01 UTC

Arvinas Inc shares are higher in after-market trading amid a broader positive sentiment following a decrease in crude oil prices and U.S. sanctions on Iran.

24 ago 2026, 19:56 UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21 ago 2026, 19:56 UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20 ago 2026, 20:01 UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19 ago 2026, 19:26 UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17 ago 2026, 19:16 UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14 ago 2026, 19:46 UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13 ago 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11 ago 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10 ago 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7 ago 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6 ago 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5 ago 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4 ago 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 ago 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 lug 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 lug 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 lug 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 lug 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 lug 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 lug 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Confronto tra pari

Modifica del prezzo

Arvinas Inc Previsione

Obiettivo di Prezzo

By TipRanks

80.51% in crescita

Previsioni per 12 mesi

Media 14.964 USD  80.51%

Alto 21 USD

Basso 8.68 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arvinas Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

5

Acquista

6

Mantieni

0

Vendi

Sentiment

By Acuity

115 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.